Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. is a biopharmaceutical company dedicated to commercializing innovative therapeutic products that address significant unmet patient needs, primarily within the dermatology sector. Headquartered in Durham, North Carolina, the company focuses on developing and bringing to market safe and efficacious treatments for various skin conditions.

The company's flagship product is ZELSUVMI™ (berdazimer) topical gel, 10.3%, which received U.S. Food and Drug Administration (FDA) approval in 2024 for the treatment of molluscum contagiosum and was subsequently launched in July 2025. Pelthos' product portfolio also includes Xepi® (ozenoxacin) Cream, 1%, a topical antibiotic for impetigo acquired in 2025, and Xeglyze® (abametapir), a topical treatment for head lice acquired in January 2026. These products leverage the company's proprietary nitric oxide-based technology platform, NITRICIL™.

Pelthos Therapeutics Inc. became a publicly traded entity on the NYSE American exchange under the ticker symbol "PTHS" in July 2025, following a merger with Channel Therapeutics Corporation and a concurrent $50.1 million private placement. Scott M. Plesha serves as the Chief Executive Officer, and John M. Gay was appointed Chief Financial Officer in April 2026. The company reported strong initial commercial performance for ZELSUVMI™, with net product revenue reaching $16.2 million from its July 2025 launch through December 2025.